Please login to the form below

Not currently logged in

Dr Ulf Jungnelius joins Oasmia Pharmaceuticals

He becomes senior medical advisor

Oasmia Pharmaceuticals Dr Ulf JungneliusOasmia Pharmaceuticals has appointed Dr Ulf Jungnelius as its new senior medical advisor.

He brings over 40 years of experience in oncology clinical research and development to the Uppsala, Sweden-based firm, having held leading positions in oncology at Eli Lilly, Pfizer and Takeda.

Most recently, Dr Jungnelius served as vice president, CR&D oncology at Celgene and continues serve as a partner for Healthcom, a healthcare technology company based in the US.

Julian Aleksov, executive chairman of Oasmia, said: “We are thrilled to add Dr Ulf Jungnelius, an individual with a very strong therapeutic area expertise and who has been a key driver in taking oncology blockbusters to regulatory approval and commercial success, to the Oasmia Pharmaceutical team.”

Meanwhile, Oasmia also announced Anders Lundin's resignation as chief financial officer.

Lundin joined the oncology drug developer in 2014, having previously served as head of finance at Galderma, a Swiss dermatology firm.

He will leave the company to pursue other business opportunities on 31 March.

5th February 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...